UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Advances in the Treatment of Paraproteinemic Neuropathy

Current treatment options in neurology, 2017-12, Vol.19 (12), p.43-43, Article 43

2017

Volltextzugriff (PDF)

Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma

Haematologica (Roma), 2007-01, Vol.92 (1), p.35-41

2007

Volltextzugriff (PDF)

Regular assessment of serum vascular endothelial growth factor levels to monitor POEMS syndrome

Neurological sciences, 2024-02, Vol.45 (2), p.727-733

2024

Volltextzugriff (PDF)

High-Dose Chemotherapy in Poor-Prognosis Adult Small Round-Cell Tumors: Clinical and Molecular Results From a Prospective Study

Journal of clinical oncology, 2002-04, Vol.20 (8), p.2181-2188

2002

Volltextzugriff (PDF)

Clinical, electrophysiological and VEGF 2-year response after lenalidomide or stem cell transplantation in patients with POEMS syndrome

Journal of neurology, neurosurgery and psychiatry, 2019-03, Vol.90 (3), p.367-368

2019

Volltextzugriff (PDF)

Which Is the Best Mobilizing Regimen in POEMS Syndrome? a Retrospective Italian Study of Two Haematological Centres

Blood, 2018-11, Vol.132 (Supplement 1), p.5692-5692

2018

Volltextzugriff (PDF)

Bortezomib/Cyclophosphamide/Dexamethasone Versus Lenalidomide/Cyclophosphamide/Dexamethasone in Multiple Myeloma Patients at First Relapse: Final Results of a Phase III Study

Blood, 2017-12, Vol.130 (Suppl_1), p.836-836

2017

Volltextzugriff (PDF)

Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function

Clinical therapeutics, 2006-06, Vol.28 (6), p.953-959

2006

Volltextzugriff (PDF)

Superior PFS2 with VTD Vs TD for Newly Diagnosed, Transplant Eligible, Multiple Myeloma (MM) Patients: Updated Analysis of Gimema MMY-3006 Study

Blood, 2014-12, Vol.124 (21), p.196-196

2014

Volltextzugriff (PDF)

Pilot Study with Lenalidomide in Patients with POEMS Syndrome

Blood, 2011-11, Vol.118 (21), p.4612-4612

2011

Volltextzugriff (PDF)

Role of Reduced-Intensity Conditioning Followed by Allogeneic Stem Cell Transplantation In Patients with Multiple Myeloma Relapsing After Autograft: a Donor Versus No Donor Analysis

Blood, 2010-11, Vol.116 (21), p.3534-3534

2010

Volltextzugriff (PDF)

Vertebroplasty for pain relief and spinal stabilization in multiple myeloma

Neurological sciences, 2010-04, Vol.31 (2), p.151-157

2010

Volltextzugriff (PDF)

The Association of a Salvage Treatment Containing Novel Agents Followed by Allogeneic Stem Cell Transplantation with Reduced-Intensity Conditioning Regimen Improves Overall Survival and Time-to-Progression in Multiple Myeloma Patiens Relapsing After Autologous Stem Cell Transplantation: A Multicentric Retrospective Study Based On Donor Availability

Blood, 2009-11, Vol.114 (22), p.4320-4320

2009

Volltextzugriff (PDF)

Better Outcome with Tandem High DOSE CHEMOTHERAPY and AUTOLOGOUS STEM CELLS TRANSPLANT IN Relapsed/Refractory HODGKIN LYMPHOMA PATIENTS Which Reached COMPLETE REMISSION AFTER Ifosfamide- Gemcitabine-Vinorelbine Scheme (IGEV)

Blood, 2009-11, Vol.114 (22), p.1213-1213

2009

Volltextzugriff (PDF)

Isolated massive meningeal progression in aggressive non Hodgkin's lymphoma

Haematologica (Roma), 2002-04, Vol.87 (4), p.EIM15

2002

Volltextzugriff (PDF)

Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Myeloma: Kinetics of Neutropenia and Thrombocytopenia and Time-to-Event Results

Clinical lymphoma & myeloma, 2009-04, Vol.9 (2), p.145-150

2009

Volltextzugriff (PDF)

Superior Rate of Complete Response with up-Front Velcade-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma Is Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities

Blood, 2008-11, Vol.112 (11), p.1662-1662

2008

Volltextzugriff (PDF)

A Prospective, Randomized, Phase III Study of Melphalan 200 mg/m2 (MEL200) Versus Melphalan 100 mg/m2 (MEL100) in Newly Diagnosed Myeloma Patients

Blood, 2006-11, Vol.108 (11), p.55-55

2006

Volltextzugriff (PDF)

Factors Affecting Outcome of Patients with Refractory/Relapsed Hodgkin's Disease (HD) Treated with IGEV Chemotherapy (CT) and High Dose Consolidation Therapy (HDT) with Stem Cell Rescue

Blood, 2005-11, Vol.106 (11), p.2091-2091

2005

Volltextzugriff (PDF)

1 – 25 von 203

Suche als RSS-Feed

Aktive Filter

ThemaHematology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(187)
Mit Volltextzugriff
(180)

Publikationsform

Artikel
(194)
Berichte
(6)
Bücher
(3)

Sprache

Englisch
(203)

Erscheinungsjahr

n.n

Thema

Science & Technology
(137)
Life Sciences & Biomedicine
(127)
Humans
(102)
Infectious Diseases
(72)
Male
(67)
Female
(59)
Hiv
(47)
Hiv Infections - Drug Therapy
(42)
Human Immunodeficiency Virus
(40)
Microbiology
(38)
Adult
(35)
Immunology
(34)
Middle Aged
(32)
Pharmacology & Pharmacy
(28)
Hiv Infections - Virology
(23)
Virology
(21)
Aids
(20)
Infections
(20)
Acquired Immune Deficiency Syndrome
(18)
Antiretroviral Drugs
(18)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Advances in the Treatment of Paraproteinemic Neuropathy

Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma

Regular assessment of serum vascular endothelial growth factor levels to monitor POEMS syndrome

High-Dose Chemotherapy in Poor-Prognosis Adult Small Round-Cell Tumors: Clinical and Molecular Results From a Prospective Study

Clinical, electrophysiological and VEGF 2-year response after lenalidomide or stem cell transplantation in patients with POEMS syndrome

Which Is the Best Mobilizing Regimen in POEMS Syndrome? a Retrospective Italian Study of Two Haematological Centres

Bortezomib/Cyclophosphamide/Dexamethasone Versus Lenalidomide/Cyclophosphamide/Dexamethasone in Multiple Myeloma Patients at First Relapse: Final Results of a Phase III Study

Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function

Superior PFS2 with VTD Vs TD for Newly Diagnosed, Transplant Eligible, Multiple Myeloma (MM) Patients: Updated Analysis of Gimema MMY-3006 Study

Pilot Study with Lenalidomide in Patients with POEMS Syndrome

Role of Reduced-Intensity Conditioning Followed by Allogeneic Stem Cell Transplantation In Patients with Multiple Myeloma Relapsing After Autograft: a Donor Versus No Donor Analysis

Bendamustine As Salvage Therapy in Multiple Myeloma: A Retrospective, Multicenter Study From the Italian Compassionate Use Program in 78 Heavily Pre-Treated Patients

Bortezomib- and Thalidomide-Induced Peripheral Neuropathy (PN) in Multiple Myeloma (MM): Clinical and Molecular Analysis of 474 Patients Treated with Thalidomide-Dexamethasone (TD) or Bortezomib-TD (VTD)

Vertebroplasty for pain relief and spinal stabilization in multiple myeloma

Better Outcome with Tandem High DOSE CHEMOTHERAPY and AUTOLOGOUS STEM CELLS TRANSPLANT IN Relapsed/Refractory HODGKIN LYMPHOMA PATIENTS Which Reached COMPLETE REMISSION AFTER Ifosfamide- Gemcitabine-Vinorelbine Scheme (IGEV)

Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study

A Phase III Study of Enoxaparin vs Aspirin vs Low-Dose Warfarin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Thalidomide Based-Regimens

Melphalan 200 Mg/m2 (Mel200) Versus Melphalan 100 Mg/m2 (Mel100) in Newly Diagnosed Myeloma Patients: A Prospective, Randomized Phase III Study

Isolated massive meningeal progression in aggressive non Hodgkin's lymphoma

Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Myeloma: Kinetics of Neutropenia and Thrombocytopenia and Time-to-Event Results

Superior Rate of Complete Response with up-Front Velcade-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma Is Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities

A Prospective, Randomized, Phase III Study of Melphalan 200 mg/m2 (Mel200) Versus Melphalan 100 mg/m2 (Mel100) in Newly Diagnosed Myeloma Patients

A Prospective, Randomized, Phase III Study of Melphalan 200 mg/m2 (MEL200) Versus Melphalan 100 mg/m2 (MEL100) in Newly Diagnosed Myeloma Patients

Factors Affecting Outcome of Patients with Refractory/Relapsed Hodgkin's Disease (HD) Treated with IGEV Chemotherapy (CT) and High Dose Consolidation Therapy (HDT) with Stem Cell Rescue

Aktive Filter

Suchergebnisse filtern